Figure 2.

Osteoclastogenic effect of IL-1β on osteoclast formation and their bone-absorbing ability. BMMs were treated with various doses of RANKL. TRAP-positive multinucleated cells with three or more nuclei were counted as osteoclasts. In both the ‘early’ (A) and the ‘late’ (B) phase of osteoclastogenesis, IL-1β increased the number of osteoclasts and their bone-absorbing ability in a dose-dependent manner. Values are the means ± SD of 3 independent experiments. ^*P<0.001 compared with Nil. Nil, control group.